Supplementary Methods S1 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Jason J. Zoeller(Harvard University), Puja Sapra(Unknown)
Cited by 0
Related Papers
Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
|Clinical Cancer Research|2020|21